Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.58 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.56 |
| ▸ | WIZ | O95785 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648403 | 1.00 | CRBN (0.58) | CRBNIKZF2WIZCSNK1A1ESR1 | |
| SCHEMBL20372613 | 1.00 | CRBN (0.58) | CRBNIKZF2WIZCSNK1A1ESR1 | |
| Hydrochloric Acid SCHEMBL31181025 | 0.99 | CRBN (0.57) | CRBNIKZF2WIZCSNK1A1ESR1 | |
| SCHEMBL30942549 | 0.98 | IKZF2 (0.56) | CRBNIKZF2WIZCSNK1A1ESR1 | |
| SCHEMBL27302560 | 0.98 | IKZF2 (0.56) | CRBNIKZF2WIZCSNK1A1ESR1 | |
| SCHEMBL30942236 | 0.96 | CRBN (0.54) | CRBNIKZF2WIZCSNK1A1ESR1 | |
| SCHEMBL27302539 | 0.96 | CRBN (0.54) | CRBNIKZF2WIZCSNK1A1ESR1 | |
| SCHEMBL20235035 | 0.94 | CRBN (0.56) | CRBNIKZF2WIZCSNK1A1ESR1 | |
| SCHEMBL27302693 | 0.93 | IKZF2 (0.55) | CRBNIKZF2WIZCSNK1A1ESR1 | |
| SCHEMBL30942540 | 0.92 | CRBN (0.53) | CRBNIKZF2WIZCSNK1A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2022120355-A1 | TEAD DEGRADERS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | CRBN 276/4885IKZF2 2302/4885WIZ 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.